New Delhi : Dr Reddy’s Laboratories (DRL) in an announcement stated that their acute migraine treatment injection ZembraceSymTouch is now commercially available in the US market.
In a BSE filling, the company said that ‘Promius Pharma LLC’, a subsidiary of DRL announced that ZembraceSymTouch injection is now commercially available in the US.
They received an approval from the US Food and Drug Administration (USFDA) for ZembraceSymTouch injection in January this year. ZembraceSymTouch is available as a prefilled, ready to use, single dose disposable injector.
At the time of USFDA approval, DRL had said the new product will be marketed in the US by Promius Pharma.
“ZembraceSymTouch is the first branded product in the company’s neurology portfolio,” DRL Executive Vice President Propriety Products Group, Raghav Chari said. (ANI)